UCLA researchers have found that embryonic stem cells and skin cells reprogrammed into embryonic-like cells have inherent molecular differences, demonstrating for the first time that the two cell types are clearly distinguishable from one another.
The data from the study suggest that embryonic stem cells and the reprogrammed cells, known as induced pluripotent stem (iPS) cells, have overlapping but still distinct gene expression signatures. The differing signatures were evident regardless of where the cell lines were generated, the methods by which they were derived or the species from which they were isolated, said William Lowry, a researcher with
Discarded fallopian tubes from hysterectomies could be a good source of donor stem cells, say researchers.
Work shows they are an abundant source of the immature cells that have the potential to become a variety of the body’s tissues, like muscle and bone.
The discovery offers another “ethical” route to creating stem cell treatments for diseases like arthritis without using embryos.
The findings are published in The Journal of Translational Medicine.
Experts have already shown that getting mesenchymal stem cells from umbilical cords, menstrual blood, teeth and fat tissue is viable.
The latest work by a Brazilian team from the University of São
Stem-cell firm BioTime said this week that it will open a subsidiary in China called BioTime Asia to expand its stem cell therapeutics and research tools to the Asian market.
BioTime Asia will be based at the Nanshan Memorial Medical Institute, or NSMMI, and will clinically develop and market therapeutic stem cell products in China and market stem cell research products in China and other Asian countries (…)
‘Yet again the Lazio region risks missing a chance to be at the cutting edge in the country for the therapeutic use of hematopoietic stem cells, a technique that is scientifically tested and proven in terms of its efficiency,’ said Luigi Canai, the President of the Lazio Health Commission, in a statement.
‘For days the media has been reporting important progress achieved in this field of research both abroad and in Italy. Regarding this subject, a year ago on February 19 2009, the commission chaired by me approved a unified text for a law that was later approved by
The brave new world of stem cell research dangles the exciting potential for a host of leading-edge treatments that may one day help cure debilitating diseases such as Alzheimer’s, Parkinson’s and other maladies that today cannot be treated with modern medicine.
However, not much thought has been given to how those products might be regulated and how issues of legal liability may be addressed in a way that encourages scientific innovation but also protects the patients for whom these treatments might provide great relief.
Now, an attorney and law professor from the UCLA School of Law and a member of the